Literature DB >> 11169366

Early screening for fetal cardiac anomalies by transvaginal echocardiography in an unselected population: the role of operator experience.

M A Rustico1, A Benettoni, G D'Ottavio, L Fischer-Tamaro, G C Conoscenti, Y Meir, R Natale, R Bussani, G P Mandruzzato.   

Abstract

OBJECTIVES: To examine the accuracy of early transvaginal fetal echocardiography performed in an unselected population by operators with different levels of experience and to compare the results with those obtained from a referral population.
DESIGN: Prospective study.
METHODS: A series of 4785 unselected fetuses and 221 referred fetuses were screened at 13-15 weeks' gestational age by transvaginal echocardiography. For each fetus, visualization of the four-chamber view plus the origin of the great arteries was attempted. Color Doppler imaging was only performed in cases of cardiac malformations already identified by two-dimensional echocardiography. The scans were performed by seven operators with different levels of experience. Reliability was assessed by conventional transabdominal echocardiography at 20-22 weeks, by postnatal follow-up in the first 3 months of life, and/or by autopsy in all cases of termination or fetal death.
RESULTS: The rate of complete visualization (four-chamber view plus great arteries) was 47.5% in the unselected population, and 76.9% in the referral population. There were four (0.08%) true positives among the unselected fetuses, and five (2.3%) among referrals, mostly with enlarged nuchal translucency or other malformations. Among the unselected fetuses, nine false negatives were detected by transabdominal echocardiography. Improvement in the operators' ability to recognize cardiac anomalies in unselected population was disappointing and was influenced more by individual approach than by the number of examinations performed.
CONCLUSIONS: Early screening for cardiac anomalies among unselected fetuses is ill-advisable. The usefulness of an early approach is confirmed in high risk fetuses or in the presence of enlarged nuchal translucency when performed by expert operators.

Entities:  

Mesh:

Year:  2000        PMID: 11169366     DOI: 10.1046/j.1469-0705.2000.00291.x

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  7 in total

1.  My approach to performing a perinatal or neonatal autopsy.

Authors:  H C Wainwright
Journal:  J Clin Pathol       Date:  2006-07       Impact factor: 3.411

Review 2.  First trimester ultrasound: current approaches and practical pitfalls.

Authors:  Ozgur Oztekin
Journal:  J Med Ultrason (2001)       Date:  2009-08-25       Impact factor: 1.314

3.  Impact of fetal echocardiography.

Authors:  John M Simpson
Journal:  Ann Pediatr Cardiol       Date:  2009-01

4.  Early Detection of Fetal Malformation, a Long Distance Yet to Cover! Present Status and Potential of First Trimester Ultrasonography in Detection of Fetal Congenital Malformation in a Developing Country: Experience at a Tertiary Care Centre in India.

Authors:  Namrata Kashyap; Mandakini Pradhan; Neeta Singh; Sangeeta Yadav
Journal:  J Pregnancy       Date:  2015-11-23

5.  Care-related factors associated with antepartal diagnosis of intrauterine growth restriction: a case-control study.

Authors:  Sinja Alexandra Ernst; Anna Reeske; Jacob Spallek; Knud Petersen; Tilman Brand; Hajo Zeeb
Journal:  BMC Pregnancy Childbirth       Date:  2014-10-31       Impact factor: 3.007

6.  Performance of different scan protocols of fetal echocardiography in the diagnosis of fetal congenital heart disease: a systematic review and meta-analysis.

Authors:  Yifei Li; Yimin Hua; Jie Fang; Chuan Wang; Lina Qiao; Chaomin Wan; Dezhi Mu; Kaiyu Zhou
Journal:  PLoS One       Date:  2013-06-04       Impact factor: 3.240

7.  Fetal Intelligent Navigation Echocardiography (FINE) Detects 98% of Congenital Heart Disease.

Authors:  Lami Yeo; Suchaya Luewan; Roberto Romero
Journal:  J Ultrasound Med       Date:  2018-03-30       Impact factor: 2.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.